Laser-Assisted Prostaglandin Analogs in the Treatment of Hypopigmented Scars: A Systematic Review
- PMID: 37720195
- PMCID: PMC10503939
Laser-Assisted Prostaglandin Analogs in the Treatment of Hypopigmented Scars: A Systematic Review
Abstract
Background: Hypopigmented scars are challenging to treat due to a lack of effective treatments and often transient results. Recent reports suggest that prostaglandin analog-induced hyperpigmentation may have favorable dermatological applications.
Objective: Analyze previous studies involving the use of prostaglandin analogs in the treatment of hypopigmented scars.
Methods: PubMed/Medline was queried through 10/01/2022 with the following search terms: (bimatoprost AND scar), (latanoprost AND scar), (travoprost AND scar), (prostaglandin analogs AND hypopigmented scars), (PGF2alpha AND hyperpigmentation), (prostaglandin analogs AND hyperpigmentation).
Results: In total, 88 unique studies were reviewed for eligibility. Five studies met inclusion criteria including two prospective, double-blinded, randomized (only one was placebo-controlled), one prospective case series, one retrospective chart review, and one case report; comprising a total of 87 patients. All five studies utilized topical prostaglandin analogs as an adjunctive treatment via laser-assisted delivery. While both, the placebo-controlled and non-placebo-controlled, trials reported more than 75 percent of patients experienced at least 50 percent or more (Grade 3 or higher) improvement, the retrospective study reported 100 percent of patients experienced at least 75 percent or more (Grade 4 or higher) improvement, measured as scar repigmentation. The prospective case series and the reported single case showed overall qualitative improvement in all patients measured as repigmentation of hypopigmented and depigmented scars.
Limitations: Different laser devices, parameters, treatment frequency, and follow-up timepoints.
Conclusion: All studies evaluated demonstrated favorable treatment outcomes with no reported adverse events. Additional, large randomized controlled trials are needed to fully assess the effectiveness and long-term safety of PGF2α agonists for hypopigmented scars.
Keywords: bimatoprost; hyperpigmentation; hypopigmented scars; lasers; prostaglandin analogs; skin of color; systematic review.
Copyright © 2023. Matrix Medical Communications. All rights reserved.
Conflict of interest statement
DISCLOSURES: The authors declare no relevant conflicts of interest for this study.
Figures
References
-
- Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: Beyond the eyelashes. Journal of the American Academy of Dermatology. 2015/04/01/ 2015;72(4):712–716. - PubMed
-
- Kanokrungsee S, Khunkhet S, Rojhirunsakool S et al. Triple combination therapy of narrowband ultraviolet B, fractional carbon dioxide laser and topical bimatoprost 0.01% for non-segmental vitiligo on non-facial areas: A randomized half-body, double-blind, placebo-controlled, comparative study. Dermatol Ther. Jan. 2022;35(1):e15198. - PubMed
-
- Waibel JS, Rudnick A, Arheart KL et al. Repigmentation of Hypopigmentation: Fractional Lasers vs Laser-Assisted Delivery of Bimatoprost vs Epidermal Melanocyte Harvesting System. J Drugs Dermatol. Nov 1. 2019;18(11):1090–1096. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous